Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biosimilar entities : Amgen inc. save search
Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances
Published: 2024-02-14 (Crawled : 20:00) - prnewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.26%
H: 0.87%
C: 0.32%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
biosimilar report global therapy growth market
Biosimilar Hormones Global Market Report 2024 - Niche Sectors Record Notable Market Contributions
Published: 2024-02-14 (Crawled : 03:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
biosimilar report global market
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
United States Biosimilar Market Report 2023: Sector is Expected to Reach $50.68 Billion in 2027 at a CAGR of 40.17%
Published: 2023-06-30 (Crawled : 19:00) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
biosimilar report expected reach market
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Published: 2023-05-25 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -0.89%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: -1.2%
biosimilar authorization ema
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Published: 2023-02-06 (Crawled : 07:00) - globenewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -2.93%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.12%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.62%
fda biosimilar application license
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -0.74%
H: 1.16%
C: 0.69%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.9%
H: 0.0%
C: -0.58%
humira biosimilar
Biosimilar Therapeutic Peptides Global Market to Reach $3.5 Billion by 2026 at a CAGR of 30.3%
Published: 2022-12-06 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 8.46%
C: 8.46%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -1.97%
H: 0.05%
C: 0.05%
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.85%
H: 0.46%
C: -0.17%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.03%
H: 0.26%
C: -0.27%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.48%
H: 1.59%
C: 0.69%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.33%
H: 0.56%
C: -0.89%
global biosimilar market
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
Published: 2022-08-23 (Crawled : 14:00) - biospace.com/
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -0.57%
H: 1.88%
C: 0.59%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -0.9%
soliris candidate biosimilar positive results study
US Biosimilar Market Report 2022: Rising Prevalence of Cancer & Increasing Health Expenditure Fueling Growth
Published: 2022-07-22 (Crawled : 17:00) - prnewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -1.78%
H: 0.0%
C: -0.1%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.37%
H: 0.52%
C: -0.39%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.42%
H: 0.94%
C: -0.34%
biosimilar report health cancer growth market
FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 7.48%
H: 0.45%
C: -4.8%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.32%
H: 0.2%
C: -1.16%
rituxan fda biosimilar
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Published: 2022-04-18 (Crawled : 22:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -1.9%
H: 0.12%
C: -3.78%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
stelara biosimilar positive results phase 3 topline
Biosimilars Market by Product, Indication and Region - Global Forecast to 2026
Published: 2021-11-10 (Crawled : 19:00) - prnewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -1.26%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
biosimilar
Biosimilars Market by Application and Geography | Global Forecast to 2025 | 17,000+ Technavio Research Reports
Published: 2021-09-22 (Crawled : 00:00) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 0.38%
H: 1.5%
C: 0.3%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.92%
H: 0.5%
C: 0.01%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 1.51%
H: 2.09%
C: -0.17%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.53%
H: 1.43%
C: 1.2%
research application biosimilar
Amgen Releases 8th Edition of Biosimilar Trends Report
Published: 2021-09-22 (Crawled : 13:00) - prnewswire.com
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: -1.35%
biosimilar
Global Biosimilar Monoclonal Antibodies (mAbs) Market in Pharmaceuticals Industry|Discover Company Insights in Technavio
Published: 2021-07-24 (Crawled : 00:20) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
| Email alert
Add to watchlist
monoclonal antibodies antibody biosimilar
Biosimilars Market to reach a value of USD 31.40 billion through 2025|Technavio
Published: 2021-07-16 (Crawled : 04:00) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: -0.07%
H: 0.29%
C: -0.79%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.84%
H: 0.05%
C: -0.35%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -1.28%
H: 2.2%
C: 0.2%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.59%
H: 0.58%
C: -0.05%
biosimilar
Global Erythropoietin Drugs Market Research Report 2021-2027: Biologics, Biosimilars, Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa
Published: 2021-07-07 (Crawled : 16:00) - prnewswire.com
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.17%
H: 0.09%
C: -0.35%
drug research biosimilar
Global $3.12 Billion Trastuzumab Biosimilars Markets, 2015-2019, 2019-2023, 2025F, 2030F
Published: 2021-05-11 (Crawled : 19:00) - prnewswire.com
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.35%
H: 0.92%
C: -0.23%
biosimilar
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.